Lin BioScience, Inc.
6696
Pozycja w akcjach
#3855
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Cena akcji
$5.05
Kapitalizacja rynkowa
$4.19B
Zmiana (1 dzień)
-5.52%
Zmiana (1 rok)
-44.55%
Kraj
TW
Handel Lin BioScience, Inc. (6696)
Kategoria
Healthcare
Historia ceny akcji dla Lin BioScience, Inc. (6696)
Najwyższa cena zamknięcia: $5.40 dnia 2026-10-01
Najniższa cena zamknięcia: $1.30 dnia 2018-10-01
Najniższa cena zamknięcia: $1.30 dnia 2018-10-01
Historia cen akcji firmy Lin BioScience, Inc. od 2018 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.89 | -3.74% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
